SS-31 (Elamipretide)

SS-31, also known in scientific literature as elamipretide, is a synthetic tetrapeptide that has attracted sustained research interest due to its selective interaction with mitochondrial membranes. Unlike broad-spectrum antioxidants, SS-31 is studied for its ability to localise within mitochondria, making it a valuable compound in experimental models examining cellular energy production, oxidative stress and mitochondrial integrity. This paper reviews the scientific rationale behind SS-31 research, its proposed mitochondrial mechanisms and its relevance within contemporary laboratory studies focused on cellular resilience and energy regulation. 

Mitochondria play a critical role in cellular metabolism by generating adenosine triphosphate (ATP), the primary energy currency of the cell. Dysfunctional mitochondrial activity has been associated with impaired cellular performance across a range of experimental models, particularly those involving high-energy tissues such as muscle and nerve cells. As a result, mitochondrial health remains a central focus in laboratory research investigating ageing, metabolic pathways and cellular stress responses. SS-31 has emerged as a compound of interest due to its targeted mitochondrial localisation and its potential to stabilise mitochondrial structure in vitro and in vivo models. 

SS-31 is distinct from conventional antioxidants because it is designed to selectively associate with cardiolipin, a phospholipid found almost exclusively in the inner mitochondrial membrane. Preclinical research suggests that this interaction may help preserve mitochondrial membrane integrity and optimise electron transport chain efficiency under experimental conditions. By targeting the site of energy production directly, SS-31 enables researchers to study mitochondrial dynamics with greater specificity than non-targeted compounds. 

Experimental data indicate that SS-31 may reduce excess reactive oxygen species generation within mitochondria while supporting ATP synthesis in laboratory models. This dual relevance to oxidative stress and energy production has made SS-31 a useful research tool in studies examining cellular endurance, mitochondrial signalling pathways and bioenergetic efficiency. 

SS-31 has been investigated across multiple experimental domains, including skeletal muscle research, neurocellular studies and models of age-associated mitochondrial decline. In laboratory settings, researchers use SS-31 to explore how stabilising mitochondrial membranes may influence cellular survival and functional output during metabolic stress. These studies do not position SS-31 as a therapeutic agent but rather as a mechanistic probe for understanding mitochondrial behaviour in controlled research environments. 

It is critical to note that SS-31 is supplied strictly for research use only. It is not approved by the Therapeutic Goods Administration (TGA) and is not intended for human or veterinary application. Ongoing research continues to evaluate its molecular interactions, optimal experimental conditions and relevance across different cellular models. 

SS-31 represents a specialised research peptide that enables targeted investigation of mitochondrial function. Its selective interaction with mitochondrial membranes distinguishes it from general antioxidants and supports its use in experimental studies focused on cellular energy, oxidative stress and mitochondrial stability. While promising within laboratory research, SS-31 remains exclusively a research compound, contributing to scientific understanding rather than clinical application. 

External Research Studies 

1. Szeto HH et al. Mitochondria-targeted peptide SS-31 protects against mitochondrial dysfunction. Proceedings of the National Academy of Sciences https://www.pnas.org/doi/10.1073/pnas.0913435107 

2. Birk AV et al. The mitochondrial-targeted compound elamipretide stabilises cardiolipin and improves bioenergetics. Journal of Molecular and Cellular Cardiology https://www.sciencedirect.com/science/article/pii/S0022282815001617 

3. Sabbah HN et al. Elamipretide and mitochondrial bioenergetics in experimental models. Circulation: Heart Failure https://www.ahajournals.org/doi/10.1161/CIRCHEARTFAILURE.114.001479